Seeking Alpha
 

Health Care Select Sect SPDR ETF (XLV)

- NYSEARCA
  • Mar. 27, 2013, 2:51 PM
    Green enters the major averages which all were down nearly 1% in the day's early going on EU bank worries. The Nasdaq +0.1% even as Apple and Google slip more than 1%. The DJIA -0.2%, the S&P 500 -0.1%, with financials the biggest drag, but energy (XLE) and healthcare (XLV) mostly higher.
    | 2 Comments
  • Mar. 22, 2013, 10:39 AM
    The health care sector (IYH, XLV) is outperforming the S&P 500 (SPY) through the year's first 11 weeks for the first time in 15 years as companies cut costs and investors bet whatever emanates from D.C. will be good for all involved. "Most of the big drug companies have experienced patent cliffs and are now repositioning themselves for growth," says one fund manager. 
    | 2 Comments
  • Mar. 15, 2013, 10:13 AM
    Health Care Select Sect SPDR ETF (XLV) announces quarterly distribution of $0.1941. 30-day SEC yield of 1.76% (as of 03/14/2013). For shareholders of record Mar. 19. Payable Mar. 25. Ex-div date Mar. 15.
    | Comment!
  • Mar. 8, 2013, 2:59 PM
    A check of sector performance YTD finds financials (XLF), consumer discretionary (XLY), healthcare (XLV), consumer staples (XLP), energy (XLE), and industrials (XLI) all ahead of SPY's 9% gain. Utilities (XLU) are lagging just a bit, but the biggest drag is tech (XLK), up 4.9%. Not bad considering Apple's 19% decline.
    | Comment!
  • Feb. 19, 2013, 9:39 AM
    It's not just Humana (-9.6%) suffering from prospective declines in reimbursement rates for Medicare Advantage plans in 2014, with UnitedHealth (UNH) -5.2%, Cigna (CI) -5.5%, Aetna (AET) -3.5% and Universal America (UAM) -8.95%.
    | 7 Comments
  • Jan. 27, 2013, 3:30 AM
    Smaller medical-device makers such as Cardica (CRDC) are tacking surcharges on to their products or warning of price increases to cover a 2.3% sales tax that came into force on Jan. 1 as part of Obamacare. Larger manufacturers like Medtronic (MDT) and GE Healthcare (GE) haven't explicitly added extra fees but are expected to bake them into contract renewals.
    | 13 Comments
  • Jan. 24, 2013, 1:31 PM
    A look at the relative strength of S&P 500 sectors vs. the overall average over the past year finds 3 - Consumer Discretionary (XLY), Financials (XLF), and Health Care (XLV) outperforming. Big outperformers a few months back, Telecom (IYZ) and Utilities (XLU) now trail. Underperforming badly not long ago, Energy (XLE) and Industrials (XLI) claw their way back.
    | 2 Comments
  • Jan. 24, 2013, 4:48 AM
    The FDA won't appeal a decision to overturn the conviction of a salesmen who was found guilty of marketing narcolepsy drug Xyrem for treating drowsiness and chronic fatigue, two conditions for which the medicine wasn't approved. A court quashed the conviction because it said FDA regulations violated free speech in a decision that could have wide ramifications for the agency's ability to regulate off-label drug marketing.
    | 3 Comments
  • Jan. 8, 2013, 3:29 PM
    Vanguard's recent expense reduction means 9 of its 10 sector ETFs are now the cheapest available to U.S. investors. With an annual expense ratio of just 0.14%, VOX, VPU, VCR, VDC, VDE, VHT, VIS, VGT, and VAW stack up favorably vs. the 0.18% charged  by State Street's Sector SPDRs (XLU, XLY, XLP, XLE, XLF, XLV, XLK, XLI, XLB and XTL which charges 0.35%) and the 0.47%-0.48% iShares sector ETFs (RXI, KXI, IYE, IYF, IYZ, IYH, IDU, IYW, IYM, IYJ) charge. At 0.19%, Vanguard Financials (VFH) is still slightly more expensive than the Financial SPDR (XLF).
    | 2 Comments
  • Jan. 8, 2013, 6:04 AM
    Healthcare spending rose at a record low pace of 3.9% to $2.7T in 2011 as patients continued to cut back on medical services amid the economic slump. The growth was the same as in 2010 and 2009, and well below the 8% prior to the financial crisis. However, there are signs the rise in spending could be speeding up again, with expenditure on drugs increasing by 2.9% in 2011 vs 0.4% in 2010, and on doctors' visits by 4.3%.
    | Comment!
  • Jan. 7, 2013, 5:33 PM
    The return of $10B-plus drug deals may be here as pharmaceutical companies appear to be gearing up to start buying again. Five of the largest U.S. drug makers have spent the last several years building up their cash positions in anticipation of expiring patents. Now, with nearly $70B in cash equivalents at their disposal, all eyes are on JPMorgan’s annual health-care conference in San Francisco, where the big drug makers will likely be on the hunt for assets to fill revenue holes left by expired patents.
    | 2 Comments
  • Jan. 7, 2013, 9:16 AM
    With the S&P at a new bull market high, Bespoke looks at sector performance since the last peak on Sept. 14. Leading the pack in the 4-month span are the financials (XLF) +5.2%, followed by Industrials (XLI) +3.6%, and Healthcare (XLV) +3.5%. Bringing up the rear are tech (XLK) -6.9% and Energy (XLE) -3.4%.
    | Comment!
  • Jan. 2, 2013, 9:44 AM
    The Street's Adam Feuerstein makes 13 biotech stock predictions for 2013, with his number one being that the U.S. launch of Arena Pharmaceuticals' (ARNA) and Eisai's weight-loss pill Belviq "will be a major disappointment." Feuerstein also reckons that Belviq will fail to receive European approval.
    | 17 Comments
  • Jan. 1, 2013, 11:40 AM
    Financial services ETFs (XLF, IPF, IXG led all sector ETFs in 2012, followed by consumer discretionary (XLY, IPD, RXI), healthcare (XLV, IRY, IXJ) and tech (XLK, IPK IXN). Utilities (XLU, IPU, JXI) and telecom (IST, IXP) underperformed.
    | Comment!
  • Jan. 1, 2013, 6:49 AM
    The number of drugs that the FDA authorized in 2012 rose to 39 from 30 last year and 21 in 2010, with the figure the highest since 53 in 1996. It also includes 10 medicines with fast-track status. The increase in approvals should help offset the patent cliff, which cost major U.S. and European drug companies $31B in revenues last year. (graph of approvals)
    | Comment!
  • Dec. 9, 2012, 2:27 AM
    The Supreme Court will review a "pay for delay" case in which Solvay, now owned by Abbott Labs (ABT), paid three generic drug companies to up to $40M a year, including Watson (WPI), to postpone making copycat versions of Solvay's Androgel testosterone treatment. The case has industry wide ramifications, with the FTC saying the practice costs customers $3.5B a year. (previous)
    | 1 Comment
Visit Seeking Alpha's
XLV vs. ETF Alternatives
XLV Description
The Health Care Select Sector SPDR® Fund, before expenses, seeks to closely match the returns and characteristics of the Health Care Select Sector Index. Our approach is designed to provide portfolios with low portfolio turnover, accurate tracking, and lower costs.
See more details on sponsor's website
Sector: Healthcare
Country: United States
ETF Hub
Find the right ETFs for your portfolio: Visit Seeking Alpha's ETF Hub